Deadline Alert: Inspire Medical Systems (INSP) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit due to significant operational issues and a drastic reduction in earnings guidance following the announcement of delays in the launch of its new sleep apnea device, Inspire V [2][4]. Company Performance - On August 4, 2025, Inspire disclosed that the launch of Inspire V was delayed due to multiple issues, including inadequate training and onboarding of treatment centers, software update delays, and excess inventory leading to poor demand [2]. - The company reduced its 2025 earnings guidance by over 80%, from a range of $2.20 to $2.30 per share to a new range of $0.40 to $0.50 per share [2]. Stock Market Reaction - Following the announcement on August 5, 2025, Inspire's stock price dropped by $42.04, or 32.4%, closing at $87.91 per share, resulting in significant losses for investors [3]. Legal Allegations - The class action complaint alleges that during the class period, the defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and operations [4]. - Specific allegations include poor demand for Inspire V due to surplus inventory, incomplete training for treatment centers, and failure to ensure necessary IT systems and Medicare reimbursement were in place at launch [4].